Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions

被引：43

作者：

Chang, Chih-Jung ^{[1
,2
,3
,4
,5
,6
]}

Chen, Chun-Bing ^{[1
,2
,3
,4
,5
,6
,7
,8
,9
,10
]}

Hung, Shuen-Iu ^{[1
,2
,3
,4
,7
]}

Ji, Chao ^{[11
]}

Chung, Wen-Hung ^{[1
,2
,3
,4
,5
,6
,7
,8
,9
,12
,13
]}

机构：

[1] Chang Gung Mem Hosp, Dept Dermatol, Taipei, Taiwan

[2] Chang Gung Mem Hosp, Drug Hypersensit Clin & Res Ctr, Taipei, Taiwan

[3] Chang Gung Mem Hosp, Dept Dermatol, Keelung, Taiwan

[4] Chang Gung Mem Hosp, Drug Hypersensit Clin & Res Ctr, Keelung, Taiwan

[5] Huaqiao Univ, Xiamen Chang Gung Hosp, Sch Med, Cent Res Lab,Dept Dermatol, Xiamen, Peoples R China

[6] Huaqiao Univ, Xiamen Chang Gung Hosp, Sch Med, Xiamen Chang Gung Allergol Consortium, Xiamen, Peoples R China

[7] Chang Gung Mem Hosp, Dept Med Res, Canc Vaccine & Immune Cell Therapy Core Lab, Taoyuan, Taiwan

[8] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[9] Chang Gung Mem Hosp, Whole Genome Res Core Lab Human Dis, Keelung, Taiwan

[10] Chang Gung Univ, Grad Inst Clin Med Sci, Taoyuan, Taiwan

[11] Fujian Med Univ, Affiliated Hosp 1, Dept Dermatol, Fuzhou, Peoples R China

[12] Tsinghua Univ, Beijing Tsinghua Chang Gung Hosp, Sch Clin Med, Dept Dermatol, Beijing, Peoples R China

[13] Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2020年 / 11卷

关键词：

drug hypersensitivity; pharmacogenetics; severe cutaneous adverse reactions; human-leukocyte antigen; T cell receptor; STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; COST-EFFECTIVENESS ANALYSIS; HLA CLASS-I; INDUCED LIVER-INJURY; HLA-B-ASTERISK-1502; ALLELE; T-CELLS; HYPERSENSITIVITY REACTIONS; JAPANESE PATIENTS; ALLOPURINOL HYPERSENSITIVITY;

D O I：

10.3389/fphar.2020.00969

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS), are idiosyncratic and unpredictable drug-hypersensitivity reactions with a high-mortality rate ranging from 10% to over 30%, thus causing a major burden on the healthcare system. Recent pharmacogenomic studies have revealed strong associations between SCAR and the genes encoding human-leukocyte antigens (HLAs) or drug-metabolizing enzymes. Some of pharmacogenetic markers have been successfully applied in clinical practice to protect patients from SCAR, such as HLA-B*15:02 and HLA-A*31:01 for new users of carbamazepine, HLA-B*58:01 for allopurinol, and HLA-B*57:01 for abacavir. This article aims to update the current knowledge in the field of pharmacogenomics of drug hypersensitivities or SCAR, and its implementation in the clinical practice.

引用

页数：11

共 108 条

[31] Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China [J].

He, Xiao-Jing ;

Jian, Ling-Yan ;

He, Xiao-Lin ;

Wu, Yan ;

Xu, Yuan-Yuan ;

Sun, Xiao-Jie ;

Miao, Li-Yan ;

Zhao, Li-Mei .

PHARMACOLOGICAL REPORTS, 2013, 65 (05) :1256-1262

[32] Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing [J].

Hershfield, M. S. ;

Callaghan, J. T. ;

Tassaneeyakul, W. ;

Mushiroda, T. ;

Thorn, C. F. ;

Klein, T. E. ;

Lee, M. T. M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (02) :153-158

[33] Genetic variations in HLA-B region and hypersensitivity reactions to abacavir [J].

Hetherington, S ;

Hughes, AR ;

Mosteller, M ;

Shortino, D ;

Baker, KL ;

Spreen, W ;

Lai, E ;

Davies, K ;

Handley, A ;

Dow, DJ ;

Fling, ME ;

Stocum, M ;

Bowman, C ;

Thurmond, LM ;

Roses, AD .

LANCET, 2002, 359 (9312) :1121-1122

[34] Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir [J].

Hetherington, S ;

McGuirk, S ;

Powell, G ;

Cutrell, A ;

Naderer, O ;

Spreen, B ;

Lafon, S ;

Pearce, G ;

Steel, H .

CLINICAL THERAPEUTICS, 2001, 23 (10) :1603-1614

[35] HLA-B*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin-Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan Project [J].

Hikino, Keiko ;

Ozeki, Takeshi ;

Koido, Masaru ;

Terao, Chikashi ;

Kamatani, Yoichiro ;

Mizukawa, Yoshiko ;

Shiohara, Tetsuo ;

Tohyama, Mikiko ;

Azukizawa, Hiroaki ;

Aihara, Michiko ;

Nihara, Hiroyuki ;

Morita, Eishin ;

Murakami, Yoshinori ;

Kubo, Michiaki ;

Mushiroda, Taisei .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (05) :1170-1178

[36] Adverse cutaneous drug eruptions: current understanding [J].

Hoetzenecker, W. ;

Naegeli, M. ;

Mehra, E. T. ;

Jensen, A. N. ;

Saulite, I. ;

Schmid-Grendelmeier, P. ;

Guenova, E. ;

Cozzio, A. ;

French, L. E. .

SEMINARS IN IMMUNOPATHOLOGY, 2016, 38 (01) :75-86

[37] Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity [J].

Hughes, DA ;

Vilar, FJ ;

Ward, CC ;

Alfirevic, A ;

Park, BK ;

Pirmohamed, M .

PHARMACOGENETICS, 2004, 14 (06) :335-342

[38]

Hung SI, 2010, PHARMACOGENOMICS, V11, P349, DOI [10.2217/pgs.09.162, 10.2217/PGS.09.162]

[39] Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions [J].

Hung, Shuen-Lu ;

Chung, Wen-Hung ;

Jee, Shiou-Hwa ;

Chen, Wen-Chieh ;

Chang, Yun-Ting ;

Lee, Woan-Ruoh ;

hu, S-Ling Hu ;

Wu, Meng-Tse ;

Chen, Gwo-Shing ;

Wong, Tak-Wah ;

Hsiao, Pa-Fan ;

Chen, Wei-Hsuan ;

Shih, Han-Yu ;

Fang, Wu-Hsiang ;

Wei, Chun-Yu ;

Lou, Yi-Hui ;

Huang, Yau-Li ;

Lin, Juei-Jueng ;

Chen, Yuan-Tsong .

PHARMACOGENETICS AND GENOMICS, 2006, 16 (04) :297-306

[40] HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol [J].

Hung, SL ;

Chung, WH ;

Liou, LB ;

Chu, CC ;

Lin, M ;

Huang, HP ;

Lin, YL ;

Lan, JL ;

Yang, LC ;

Hong, HS ;

Chen, MJ ;

Lai, PC ;

Wu, MS ;

Chu, CY ;

Wang, KH ;

Chen, CH ;

Fann, CSJ ;

Wu, JY ;

Chen, YT .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (11) :4134-4139

← 1 2 3 4 5 6 7 8 9 10 →